Payment overview · 2025
General Payments
$584.35
37 reported records · 9 companies
Healthcare provider profile · identity verified
Eric A. Ravitz, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MISSOULA, MT · NPI 1215034681
Verified facts
What the public records show
CMS Open Payments records show Eric A. Ravitz, D.O. received $584.35 in general payments during 2025 across 37 reported records.
ABBVIE INC. accounted for 31.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Shingrix by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $184.14 | 31.5% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $172.47 | 29.5% | 16 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.26 | 8.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $40.79 | 7.0% | 2 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $36.00 | 6.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.86 | 5.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.92 | 5.0% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $25.18 | 4.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.73 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $584.35 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $172.47 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $96.45 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.02 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.47 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.79 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.86 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $30.67 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.92 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.56 | 2 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
83 | 63 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
99 | 99 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 343 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 279 | 63 |
| Oxycodone Hcl | Oxycodone Hcl | 183 | 25 |
| Omeprazole | Omeprazole | 177 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 171 | 33 |
| Montelukast Sodium | Montelukast Sodium | 161 | 20 |
| Gabapentin | Gabapentin | 158 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 15 |
| Lisinopril | Lisinopril | 132 | 29 |
| Losartan Potassium | Losartan Potassium | 123 | 24 |
| Lorazepam | Lorazepam | 113 | 21 |
| Diazepam | Diazepam | 111 | 19 |
| Meloxicam | Meloxicam | 107 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 106 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 104 | 21 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 99 | 99 |
| Tramadol Hcl | Tramadol Hcl | 90 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 11 |
| Clonazepam | Clonazepam | 88 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | suppressed |
| Metformin Hcl | Metformin Hcl | 83 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 83 | 63 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 82 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 77 | 11 |
| Alprazolam | Alprazolam | 76 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 20 |
| Baclofen | Baclofen | 72 | 14 |
| Bupropion Xl | Bupropion Hcl | 70 | suppressed |
| Aripiprazole | Aripiprazole | 68 | suppressed |
| Lamotrigine | Lamotrigine | 65 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 65 | 14 |
| Mirtazapine | Mirtazapine | 64 | suppressed |
| Furosemide | Furosemide | 61 | 11 |
| Trazodone Hcl | Trazodone Hcl | 60 | 12 |
| Sertraline Hcl | Sertraline Hcl | 59 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 11 |
| Potassium Chloride | Potassium Chloride | 54 | suppressed |
| Allopurinol | Allopurinol | 52 | 14 |
| Celecoxib | Celecoxib | 52 | 13 |
| Estradiol | Estradiol | 52 | 16 |
| Methocarbamol | Methocarbamol | 51 | 15 |
| Pregabalin | Pregabalin | 50 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 46 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 45 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 44 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Olanzapine | Olanzapine | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Simvastatin | Simvastatin | 40 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 39 | 39 |
| Famotidine | Famotidine | 39 | suppressed |
| Jardiance | Empagliflozin | 38 | suppressed |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Torsemide | Torsemide | 35 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 25 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Atenolol | Atenolol | 19 | suppressed |
| Progesterone | Progesterone, Micronized | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | 13 |
| Risperidone | Risperidone | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Eliquis | Apixaban | 17 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Cartia Xt | Diltiazem Hcl | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 11 |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Humira(Cf) | Adalimumab | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Symproic | Naldemedine Tosylate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $584.35 · 37 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, FANAPT, MAVYRET, NURTEC ODT, PENMENVY, QULIPTA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error